Document Detail


Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.
MedLine Citation:
PMID:  20883928     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The aim of this study was to evaluate the effectiveness of a combination of dronedarone and ranolazine in suppression of atrial fibrillation (AF).
BACKGROUND: Safe and effective pharmacological management of AF remains one of the greatest unmet medical needs.
METHODS: The electrophysiological effects of dronedarone (10 μmol/l) and a relatively low concentration of ranolazine (5 μmol/l) separately and in combination were evaluated in canine isolated coronary-perfused right and left atrial and left ventricular preparations as well as in pulmonary vein preparations.
RESULTS: Ranolazine caused moderate atrial-selective prolongation of action potential duration and atrial-selective depression of sodium channel-mediated parameters, including maximal rate of rise of the action potential upstroke, leading to the development of atrial-specific post-repolarization refractoriness. Dronedarone caused little or no change in electrophysiological parameters in both atrial and ventricular preparations. The combination of dronedarone and ranolazine caused little change in action potential duration in either chamber but induced potent use-dependent atrial-selective depression of the sodium channel-mediated parameters (maximal rate of rise of the action potential upstroke, diastolic threshold of excitation, and the shortest cycle length permitting a 1:1 response) and considerable post-repolarization refractoriness. Separately, dronedarone or a low concentration of ranolazine prevented the induction of AF in 17% and 29% of preparations, respectively. In combination, the 2 drugs suppressed AF and triggered activity and prevented the induction of AF in 9 of 10 preparations (90%).
CONCLUSIONS: Low concentrations of ranolazine and dronedarone produce relatively weak electrophysiological effects and weak suppression of AF when used separately but when combined exert potent synergistic effects, resulting in atrial-selective depression of sodium channel-dependent parameters and effective suppression of AF.
Authors:
Alexander Burashnikov; Serge Sicouri; José M Di Diego; Luiz Belardinelli; Charles Antzelevitch
Related Documents :
11454138 - Atrial fibrillation--where do we stand today?
18534368 - Atrial and ventricular fibrosis induced by atrial fibrillation: evidence to support ear...
10234708 - Acute testing of the rate-smoothed pacing algorithm for ventricular rate stabilization.
15653028 - Heart rate turbulence after atrial premature beats before spontaneous onset of atrial f...
20946228 - An alternative method of assessing bidirectional block for atrial flutter.
53328 - Coronary heart-attacks in east london.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  56     ISSN:  1558-3597     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-04     Completed Date:  2010-10-22     Revised Date:  2014-09-18    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1216-24     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetanilides / administration & dosage*
Action Potentials / drug effects,  physiology
Amiodarone / administration & dosage,  analogs & derivatives*
Animals
Anti-Arrhythmia Agents / administration & dosage*
Atrial Fibrillation / drug therapy*,  physiopathology*
Disease Models, Animal
Dogs
Dose-Response Relationship, Drug
Drug Synergism
Drug Therapy, Combination
Piperazines / administration & dosage*
Grant Support
ID/Acronym/Agency:
HL-47678/HL/NHLBI NIH HHS; R01 HL047678/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Acetanilides; 0/Anti-Arrhythmia Agents; 0/Piperazines; 110445-25-5/ranolazine; JQZ1L091Y2/dronedarone; N3RQ532IUT/Amiodarone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORO...
Next Document:  Prognostic value of high-dose dobutamine stress magnetic resonance imaging in 1,493 consecutive pati...